Organon & Co
$ 13.40
0.07%
09 Jun - close price
- Market Cap 3,508,347,000 USD
- Current Price $ 13.40
- High / Low $ 13.45 / 13.38
- Stock P/E 14.37
- Book Value 3.44
- EPS 0.93
- Next Earning Report -
- Dividend Per Share $0.08
- Dividend Yield 0.6 %
- Next Dividend Date 2026-06-11
- ROA 0.06 %
- ROE 0.34 %
- 52 Week High 13.48
- 52 Week Low 5.68
About
Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, Hormone replacement therapy (HRT), and anesthesia. The company sells to international markets.
Analyst Target Price
$11.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-04-30 | 2026-02-12 | 2025-11-10 | 2025-08-05 | 2025-05-01 | 2025-02-13 | 2024-10-31 | 2024-08-06 | 2024-05-02 | 2024-02-15 | 2023-11-02 | 2023-08-08 |
| Reported EPS | 0.71 | 0.63 | 1.01 | 1 | 1.02 | 0.9 | 0.87 | 1.12 | 1.22 | 0.88 | 0.87 | 1.31 |
| Estimated EPS | 0.8476 | 0.76 | 0.93 | 0.94 | 0.89 | 0.87 | 0.9 | 1.08 | 0.97 | 0.83 | 1.06 | 1.01 |
| Surprise | -0.1376 | -0.13 | 0.08 | 0.06 | 0.13 | 0.03 | -0.03 | 0.04 | 0.25 | 0.05 | -0.19 | 0.3 |
| Surprise Percentage | -16.2341% | -17.1053% | 8.6022% | 6.383% | 14.6067% | 3.4483% | -3.3333% | 3.7037% | 25.7732% | 6.0241% | -17.9245% | 29.703% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-06-11 | 2026-03-12 | 2025-12-11 | 2025-09-11 | 2025-06-12 | 2025-03-13 | 2024-12-12 | 2024-09-12 | 2024-06-13 | 2024-03-14 |
| Amount | $0.02 | $0.02 | $0.02 | $0.02 | $0.02 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 |
Next Dividend Records
| Dividend per share (year): | $0.08 |
| Dividend Yield | 0.6% |
| Next Dividend Date | 2026-06-11 |
| Ex-Dividend Date | 2026-05-11 |
Recent News: OGN
2026-06-09 11:40:13
The State Bank of India (SBI) is reportedly considering financing up to $1 billion for Sun Pharmaceutical Industries Ltd.'s $12 billion acquisition of Organon & Co. This move would mark a significant step, making it one of the largest outbound acquisitions by an Indian company and highlighting SBI's growing role in global M&A financing, partly due to recent regulatory changes by the RBI. The potential involvement underscores India's ambition for global expansion and could allow Indian companies greater access to domestic financing for international deals.
2026-06-02 12:06:00
Brodsky & Smith is investigating potential claims against the Board of Directors of Organon & Co. (OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share. The investigation focuses on whether Organon's Board breached its fiduciary duties by failing to conduct a fair process and ensuring fair value for shareholders. Shareholders are invited to contact Brodsky & Smith for more information.
2026-06-01 09:40:24
Organon & Co. has agreed to be acquired by Sun Pharmaceutical Holdings USA, Inc. for $14.00 per share in cash, a deal recommended by Organon's Board of Directors. The acquisition is subject to stockholder approval, regulatory clearances, and customary conditions, with closing expected in early 2027. Sun Pharma USA will fund the acquisition through cash on hand and a committed senior secured bridge facility.
2026-05-30 14:10:27
This page provides a detailed financial overview of Organon & Co (OGN), including its stock price, key financial metrics, recent news filings, analyst ratings, and insider trading activity. It highlights the company's performance, significant events like acquisition offers from Sun Pharma, and executive information.
2026-05-27 07:39:46
Hanmi Pharmaceutical has signed a supply agreement with Organon to export three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. This partnership expands their collaboration in Southeast Asia, with Organon handling marketing, distribution, and sales while Hanmi supplies the finished products. The agreement is set to support Hanmi's commercial expansion in the rapidly growing Southeast Asian pharmaceutical market, particularly as demand for combination therapies rises due to increasing chronic diseases.
2026-05-27 07:09:09
Hanmi Pharmaceutical has signed an agreement with Organon to supply three combination medicines for cardiovascular and respiratory therapeutic areas to Malaysia and the Philippines. Organon will handle marketing and sales in these markets, with potential for future expansion. This partnership aims to leverage the rapidly growing pharmaceutical market in Southeast Asia, particularly for combination therapies.
